Uryu, Kiyoaki
Imamura, Yoshinori http://orcid.org/0000-0002-5202-531X
Shimoyama, Rai
Mase, Takahiro
Fujimura, Yoshiaki
Hayashi, Maki
Ohtaki, Megu
Otani, Keiko
Hibino, Makoto
Horiuchi, Shigeto
Fukui, Tomoya
Fukai, Ryuta
Chihara, Yusuke
Iwase, Akihiko
Yamada, Noriko
Tamura, Yukihiro
Harada, Hiromasa
Shinozaki, Nobuaki
Shimada, Toyoshi
Tsuya, Asuka
Fukuoka, Masahiro
Minami, Hironobu
Article History
Received: 30 January 2024
Accepted: 19 March 2024
First Online: 8 April 2024
Declarations
:
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare no actual or potential conflict of interest. Some authors have received research funding, honoraria, or scholarship donations from various pharmaceutical companies and other organizations outside of the submitted work, none of which construe actual or potential conflicts of interest. KU has received speaker and consultant honoraria from Chugai, Astra Zeneca, Boehringer-Ingelheim Japan, Bristol Myers Squibb, and Nipponkayaku. YI has received speaker bureau fees/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Ono Pharm outside of the submitted work. RS has received speaker and consultant honoraria from Daiichi-Sankyo, Ono Parm, Taiho Parm, and Chugai. TF has received speaker and consultant honoraria from Astra Zeneca, Boehringer-Ingelheim Japan, and Chugai Pharmaceutical Co Ltd. HM has received speakers’ bureau fees/honoraria from Daiichi-Sankyo and Ono Pharm; research funding from Astellas-Amgen Biopharma, Bayer, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Incite, Novartis, Ono Pharm, Pfizer, and Rakuten Medical; and scholarship donations from Bayer, Chugai, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Lilly, Ono Pharmaceutical, Pfizer, Taiho Pharma, and Takeda outside the submitted work. These organizations had no role in the design, conduct, or reporting of the study.